186298-52-2

Basic information

• Product Name: 3-iodo-1-methyl-4-nitro-1H-pyrazole
• Synonyms: 3-iodo-1-methyl-4-nitro-1H-pyrazole
• CAS NO: 186298-52-2
• Molecular Weight: 252.999
• Mol File: 186298-52-2.mol

Chemical Properties

• CAS DataBase Reference: 3-iodo-1-methyl-4-nitro-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-iodo-1-methyl-4-nitro-1H-pyrazole(186298-52-2)
• EPA Substance Registry System: 3-iodo-1-methyl-4-nitro-1H-pyrazole(186298-52-2)

Safety Data

• Hazardous Substances Data: 186298-52-2(Hazardous Substances Data)

Upstream product

• 34091-53-7 3,4-diiodo-1-methylpyrazole 
• 3994-50-1 1-methyl-4-nitropyrazole 
• 20055-00-9 1-methyl-4-nitro-1H-pyrazol-3-ylamine 
• 92525-10-5 3-iodine-1-methyl-1H-pyrazole 

Downstream Products

• 66296-67-1 1-methyl-3,4-dinitropyrazole 

Relevant articles and documents

Direct iodination of 3- and 4-nitropyrazoles with a reagent based on iodine monochloride and silver sulfate

The reagent obtained from iodine monochloride and silver sulfate in sulfuric acid easily iodinates 1-methyl-3-nitropyrazole under mild conditions to give 4-iodo or 4,5-diiodo derivatives. 1-Methyl-4-nitropyrazole was also directly iodinated with this reagent for the first time.

Nitrodeiodination of 4-iodo-1-methylpyrazoles

4-Iodo-1-methylpyrazoles react with a nitrating mixture at 55°C to give the corresponding 4-nitro-1-methylpyrazoles. The qualitative dependence of the nitrodeiodination rate on the structure of the heterocycles and the reaction conditions was considered.

Compound as well as preparation method and medical application thereof

The invention provides a compound as well as a preparation method and medical application thereof, the compound has a structure as shown in a general formula (I), and can also be a tautomer, a mesomer, a raceme, an enantiomer, a diastereoisomer, or a mixture form thereof, or a pharmaceutically acceptable salt thereof. According to the compound with the structure as shown in the general formula (I)provided by the invention, a specific main chain structure and a corresponding substituent group are selected, so that the obtained compound can be used as an arginase inhibitor, is relatively high in activity, and has a potential treatment prospect in various diseases.

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein A, J, R1, R2, R3, R4, R5, R6, R7, R9, X, m and n are as described herein, compositions thereof, and methods and uses thereof.